Best of the Week
Most Popular
1. The Trump Stock Market Trap May Be Triggered - Barry_M_Ferguson
2.Why are Central Banks Buying Gold and Dumping Dollars? - Richard_Mills
3.US China War - Thucydides Trap and gold - Richard_Mills
4.Gold Price Trend Forcast to End September 2019 - Nadeem_Walayat
5.Money Saving Kids Gardening Growing Giant Sunflowers Summer Fun - Anika_Walayat
6.US Dollar Breakdown Begins, Gold Price to Bolt Higher - Jim_Willie_CB
7.INTEL (INTC) Stock Investing to Profit From AI Machine Learning Boom - Nadeem_Walayat
8.Will Google AI Kill Us? Man vs Machine Intelligence - N_Walayat
9.US Prepares for Currency War with China - Richard_Mills
10.Gold Price Epochal Breakout Will Not Be Negated by a Correction - Clive Maund
Last 7 days
Has Next UK Financial Crisis Just Started? Bank Accounts Being Frozen - 21st July 19
Silver to Continue Lagging Gold, Will Struggle to Overcome $17 - 21st July 19
What’s With all the Weird Weather?  - 21st July 19
Halifax Stopping Customers Withdrawing Funds Online - UK Brexit Banking Crisis Starting? - 21st July 19
US House Prices Trend Forecast 2019 to 2021 - 20th July 19
MICROSOFT Cortana, Azure AI Platform Machine Intelligence Stock Investing Video - 20th July 19
Africa Rising – Population Explosion, Geopolitical and Economic Consquences - 20th July 19
Gold Mining Stocks Q2’19 Results Analysis - 20th July 19
This Is Your Last Chance to Dump Netflix Stock - 19th July 19
Gold and US Stock Mid Term Election and Decade Cycles - 19th July 19
Precious Metals Big Picture, as Silver Gets on its Horse - 19th July 19
This Technology Everyone Laughed Off Is Quietly Changing the World - 19th July 19
Green Tech Stocks To Watch - 19th July 19
Double Top In Transportation and Metals Breakout Are Key Stock Market Topping Signals - 18th July 19
AI Machine Learning PC Custom Build Specs for £2,500 - Scan Computers 3SX - 18th July 19
The Best “Pick-and-Shovel” Play for the Online Grocery Boom - 18th July 19
Is the Stock Market Rally Floating on Thin Air? - 18th July 19
Biotech Stocks With Near Term Catalysts - 18th July 19
SPX Consolidating, GBP and CAD Could be in Focus - 18th July 19
UK House Building and Population Growth Analysis - 17th July 19
Financial Crisis Stocks Bear Market Is Scary Close - 17th July 19
Want to See What's Next for the US Economy? Try This. - 17th July 19
What to do if You Blow the Trading Account - 17th July 19
Bitcoin Is Far Too Risky for Most Investors - 17th July 19
Core Inflation Rises but Fed Is Going to Cut Rates. Will Gold Gain? - 17th July 19
Boost your Trading Results - FREE eBook - 17th July 19
This Needs To Happen Before Silver Really Takes Off - 17th July 19
NASDAQ Should Reach 8031 Before Topping - 17th July 19
US Housing Market Real Terms BUY / SELL Indicator - 16th July 19
Could Trump Really Win the 2020 US Presidential Election? - 16th July 19
Gold Stocks Forming Bullish Consolidation - 16th July 19
Will Fed Easing Turn Out Like 1995 or 2007? - 16th July 19
Red Rock Entertainment Investments: Around the world in a day with Supreme Jets - 16th July 19
Silver Has Already Gone from Weak to Strong Hands - 15th July 19
Top Equity Mutual Funds That Offer Best Returns - 15th July 19
Gold’s Breakout And The US Dollar - 15th July 19
Financial Markets, Iran, U.S. Global Hegemony - 15th July 19
U.S Bond Yields Point to a 40% Rise in SPX - 15th July 19
Corporate Earnings may Surprise the Stock Market – Watch Out! - 15th July 19
Stock Market Interest Rate Cut Prevails - 15th July 19
Dow Stock Market Trend Forecast Current State July 2019 Video - 15th July 19
Why Summer is the Best Time to be in the Entertainment Industry - 15th July 19
Mid-August Is A Critical Turning Point For US Stocks - 14th July 19
Fed’s Recessionary Indicators and Gold - 14th July 19
The Problem with Keynesian Economics - 14th July 19

Market Oracle FREE Newsletter

Top AI Stocks Investing to Profit from the Machine Intelligence Mega-trend

Healthcare Company Profits Sensitivity to Obamacare

Companies / Healthcare Sector Oct 31, 2009 - 02:17 PM GMT

By: Richard_Shaw


Best Financial Markets Analysis ArticleNational healthcare wherever is implemented squeezes prices and profits of the private businesses involved in the system.

Obamacare in the U.S. will be no different.  For investors in healthcare companies, it is a good idea to begin to think through which companies will be most severely negatively impacted or least impacted, to potentially make  deletions or substitutions.

One dimension of healthcare companies is research and development, which has been an important driver of future growth and value for many companies in the biotech, pharmaceutical and medical devices industries.

To the extent that the rewards of research and development are reduced by price pressures due to national healthcare, research and development will decrease, and therefore growth in sales, profits and value of those private companies will slow.

One way to begin the process of determining the sensitivity of biotech, pharmaceutical and medical device companies to a switch from a private to a public U.S. healthcare system is to identify what portion of their total revenue comes from the U.S.  Those with a greater U.S. revenue exposure are more likely to be damaged by Obamacare than those with less U.S. revenue exposure.

This chart identifies 21 healthcare companies that have expended for R&D on average for the past 7 years at 15% of sales or more, and that have a current market-cap of $10 billion or more.

Company symbols in the table image: STJ, AMGN, CELG, AGN, BMY, BSX, MRK, LLY, GILD, BIIB, JNJ, GENZ, WYE, ESALY, NVS, GSK, AZN, PFE, RHHBY, NVO, SNY, SGP.

While there are many other questions to ask about a company to judge its sensitivity to potential U.S. national healthcare, looking at geographic revenue segmentation is a good place to start.

Some, but not all, of the other factors, you will probably want to analyze as you do your investment research are:

  • current profit margins on U.S. revenue versus non-U.S. revenue
  • split of consumer products that are not covered by current insurance, nor likely to be covered by Obamacare (e.g. aspirin and cold remedies)
  • sales and growth rate contribution from the U.S. versus other countries
  • what they have already in late state development or clinical trials
  • the duration of patents on their key drugs or devices
  • the current degree of market adoption of their key drugs or devices

While the answers to the above questions could prove more important than geographic revenue segmentation, preliminary logic would say that large companies with lower U.S. revenue exposure are candidates as potential substitutes for large companies with higher U.S. revenue exposure.

Even though companies with less U.S. revenue may have substantial European revenue, the national healthcare impact from those countries is already a known.

One of our clients who is in the medical services business, told us that a national healthcare official there told him that European healthcare officials recognize that the profitable private market in the U.S. has enabled much of the research and development by healthcare companies around the world.  He said the flow of new drugs, treatments and devices that they rely upon is dependent on companies being able to profitably develop them for the U.S. market.  European officials are concerned that their national healthcare will consequently suffer a decreased flow of new drugs, treatments and devices if the U.S. eliminates its private healthcare system.

Whether that is correct, we don’t know, but it is an interesting issue from an investment perspective.  It suggests that even though there are important European companies doing research and development, they may not do so much of that if they cannot sell new products into the United States at higher prices than they can at home.

The story points to the need for a large private healthcare market somewhere to make development of new medical technology economically attractive to private companies.

Without private research and development, we are left with politically directed research which is more likely to be incremental as opposed to breakthrough. There certainly are some examples of government directed and funded research creating breakthroughs, most notably in space exploration and in military technology.  However, those types of programs were not characterized by cost containment as a key objective, but cost containment is one of the key goals in any national healthcare system.

All this leads us to think that healthcare investing would need to refocus on the “Walmarts” of healthcare (high volume, low margin); that biotech venture capital would have to be rethought; and that large pharma and device companies may need to merge to create larger more efficient, but less research oriented entities.

There will still be success stories and investment profits to be made, but not with the same old investment selection models.

We aren’t entirely sure what the new models would look like, but we do think a re-think of what a good healthcare investment would be is essential.

For starters, the U.S. versus non-U.S. revenue mix is a dimension to consider.

Approach healthcare providers, biotech companies, pharma companies, medical device companies, and medical or psychiatric REITS with an extra dose of investment research and caution until the U.S. sorts out its healthcare system plans.

Disclosure: We do not own any company identified in this article.

By Richard Shaw

Richard Shaw leads the QVM team as President of QVM Group. Richard has extensive investment industry experience including serving on the board of directors of two large investment management companies, including Aberdeen Asset Management (listed London Stock Exchange) and as a charter investor and director of Lending Tree ( download short professional profile ). He provides portfolio design and management services to individual and corporate clients. He also edits the QVM investment blog. His writings are generally republished by SeekingAlpha and Reuters and are linked to sites such as Kiplinger and Yahoo Finance and other sites. He is a 1970 graduate of Dartmouth College.

Copyright 2006-2009 by QVM Group LLC All rights reserved.

Disclaimer: The above is a matter of opinion and is not intended as investment advice. Information and analysis above are derived from sources and utilizing methods believed reliable, but we cannot accept responsibility for any trading losses you may incur as a result of this analysis. Do your own due diligence.

Richard Shaw Archive

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules